The 4 analysts offering 12-month price forecasts for Ovid Therapeutics Inc have a median target of 6.00, with a high estimate of 8.00 and a low estimate of 5.00. The median estimate represents a +57.07% increase from the last price of 3.82.
The current consensus among 7 polled investment analysts is to Buy stock in Ovid Therapeutics Inc. This rating has held steady since March, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $1.45
Reporting Date May 11
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.